Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
European Respiratory Journal · 2024
DOI: 10.1183/13993003.00233-2024 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Pierre-Régis Burgel. Beteiligte Einrichtung: Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France pierre-regis.burgel@aphp.fr. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Indoles, Aminophenols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Filière Maladies Rares MUCO-CFTR, Société Française de la Mucoviscidose, Association Vaincre la Mucoviscidose.
Abstract (Originalsprache)
Shareable abstract Lists of CFTR variants responsive and non-responsive to elexacaftor/tezacaftor/ivacaftor will help in expanding eligibility for people with cystic fibrosis carrying rare CFTR variantshttps://bit.ly/3HQioXl
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France pierre-regis.burgel@aphp.fr.
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France.
ORCID-Profile: Pierre-Régis Burgel
Förderung
- Filière Maladies Rares MUCO-CFTR
- Société Française de la Mucoviscidose
- Association Vaincre la Mucoviscidose
Zitieren
APA
Burgel, P. R. (2024). Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. European Respiratory Journal. https://doi.org/10.1183/13993003.00233-2024
Vancouver
Burgel PR. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. European Respiratory Journal. 2024. doi:10.1183/13993003.00233-2024
BibTeX
@article{Burgel2024,
author = {Burgel, Pierre-Régis},
title = {Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme},
journal = {European Respiratory Journal},
year = {2024},
doi = {10.1183/13993003.00233-2024}
}
EUVIMED